MedDataX Logo

Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia

NCT ID: NCT01371968

Last Updated: 2017-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-28

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to determine the optimal dose of alfentanil in suppressing the airway reflexes during supreme LMA removal in anaesthetized adult.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The removal of LMA may be associated with coughing, biting, agitation and airway complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient is breathing spontaneously and when the airway reflexes are still depressed. A number of techniques have been used to prevent this adverse emergence phenomenon, such as removing the tube while the patient is in deep plane of anaesthesia or administration of local anaesthetic and intravenous opioids

The administration of intravenous opioids before emergence may be useful for preventing cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and agitation during the endotracheal tube emergence. However, its use in suppressing cough in LMA patient has not been evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Airway Response

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Alfentanil optimal dose laryngeal mask airway

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

alfentanil

patient will received a dose of alfentanil in which the dose of alfentanil is determined by response of previously tested patient using Dixon up and down methods

Group Type EXPERIMENTAL

alfentanil

Intervention Type DRUG

Alfentanil is administered intravenously at the end of surgery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

alfentanil

Alfentanil is administered intravenously at the end of surgery.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rapifen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ASA I and II patients
2. Age 18 to 49 years old
3. Minor elective day care surgery (\> 20 minute and less than 2 hours) which require local anaesthetic infiltration and does not require use of long acting opioids.

Exclusion Criteria

1. Potential difficult airway
2. Reactive airway disease or sign and symptoms of upper respiratory tract infection.
3. History of cardiac, pulmonary and renal diseases
4. Body Mass Index \> 30 kgm2.
5. Risk of aspiration.
6. Poor dentition with high risk of damage.
7. Patient refusal.
Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Malaysian Society of Anaesthesiologists

OTHER

Sponsor Role collaborator

University of Malaya

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lee Chew Kiok

University of Malaya

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lee Chew Kiok, MBBS

Role: PRINCIPAL_INVESTIGATOR

Department of Anaesthesiogy, UMMC.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Malaya Medical Centre

Kuala Lumpur, , Malaysia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Malaysia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Alfentanil LMA

Identifier Type: -

Identifier Source: org_study_id